Charles River Laboratories International, Inc.
NYSE:CRLMedical - Diagnostics & Research
-$2.45 today
- Market cap
- $15.97B
- Beta
- 1.45
- P/E (TTM)
- -48.3
- EPS (TTM)
- -$3.77
Volume 0.52M
Average 0.86M
CRL Deferred Revenue (Non-current)
Payments received for goods or services the company will deliver after more than one year.
Charles River Laboratories International, Inc.NYSE: CRL
Deferred Revenue (Non-current) · Q2 FY2026 · quarter ended Jun 2026
Deferred revenue (non-current) remains negative
Q2 FY2026 deferred revenue (non-current) was $0, compared with $0 a year earlier.
Context
- Deferred revenue (non-current) amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Deferred revenue (non-current) increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue (Non-current) history
USD · from the balance sheet
- Latest · FY2025
- 45.63M USD
- Year-over-year change
- —
- 4-year CAGR
- +22.0%
| Period | Period end | Deferred Revenue (Non-current) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-27 | 45.63M | — |
| FY2024 | 2024-12-28 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 20.58M | — |
Deferred Revenue (Non-current) vs competitors
How CRL compares with its peers on the latest reported figures
- CRL's Jun 2026 deferred revenue (non-current) of $0 is the 2nd highest of the 4 companies compared; the peer median is $0.
- Deferred revenue (non-current) amounts to 0.0% of total assets for CRL, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.1M | +142.8% | — | 0.2% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CRL) | $0 | +142.8% | — | 0.0% | |
Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 245.24M | 233.91M | 276.77M | 194.61M | 213.77M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 650.38M | 752.39M | 780.38M | 720.92M | 708.86M |
| Inventory | 199.15M | 255.81M | 380.26M | 278.54M | 299.1M |
| Other Current Assets | 0 | 107.58M | 83.38M | 105.8M | 8.65M |
| Total Current Assets | 1.27B | 1.44B | 1.61B | 1.4B | 1.45B |
| Property, Plant & Equipment (Net) | 1.58B | 1.86B | 2.03B | 2.02B | 2.02B |
| Goodwill | 2.71B | 2.85B | 3.1B | 2.85B | 2.76B |
| Intangible Assets | 1.06B | 955.28M | 864.05M | 723.4M | 340M |
| Long-term Investments | 201.35M | 311.6M | 243.81M | 218.35M | 206.97M |
| Tax Assets | 40.23M | 41.26M | 40.28M | 42.18M | 67.33M |
| Other Non-current Assets | 151.54M | 148.28M | 309.38M | 278.23M | 293.19M |
| Total Non-current Assets | 5.75B | 6.16B | 6.59B | 6.13B | 5.69B |
| Total Assets | 7.02B | 7.6B | 8.2B | 7.53B | 7.14B |
| Account Payables | 198.13M | 205.92M | 168.94M | 140.34M | 148.8M |
| Short-term Debt | 101K | 0 | 0 | 0 | 61.06M |
| Tax Payables | 26.16M | 0 | 38.8M | 0 | 0 |
| Deferred Revenue | 219.7M | 264.26M | 241.82M | 248.32M | 210.42M |
| Other Current Liabilities | 307.01M | 401.65M | 431.04M | 373.43M | 392.19M |
| Total Current Liabilities | 1.03B | 1.09B | 1.06B | 994.1M | 1.12B |
| Long-term Debt | 2.92B | 2.71B | 2.65B | 2.24B | 2.55B |
| Deferred Tax Liabilities | 239.72M | 215.58M | 191.35M | 106.96M | 95.2M |
| Deferred Revenue (Non-current) | 20.58M | 0 | 0 | 0 | 45.63M |
| Other Non-current Liabilities | (30.69M) | 174.82M | 223.19M | 195.21M | (341.38M) |
| Total Non-current Liabilities | 3.4B | 3.49B | 3.48B | 3.03B | 2.8B |
| Total Liabilities | 4.43B | 4.58B | 4.54B | 4.02B | 3.92B |
| Common Stock | 505K | 509K | 513K | 511K | 492K |
| Retained Earnings | 980.75M | 1.43B | 1.89B | 1.81B | 1.39B |
| Accumulated OCI | (164.74M) | (262.06M) | (196.43M) | (317.35M) | (171.78M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 57.17M | 47.21M | 62.12M | 46.58M | 46.56M |
| Total Equity | 2.59B | 3.02B | 3.66B | 3.51B | 3.21B |
| Total Debt | 3.21B | 3.1B | 3.07B | 2.72B | 3.07B |
| Net Debt | 2.96B | 2.86B | 2.79B | 2.53B | 2.85B |
Charles River Laboratories International, Inc.
NYSE:CRL
Intrinsic Alpha fair value
Locked
Current Price
$333.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.